# LRMR — Larimar Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** LRMR  
**Sources:** 17  
**Published:** 2026-10-31  
**Canonical:** https://app.k3vl4r.com/research/deep-research-lrmr-larimar-therapeutics-inc-catalysts-narrative-risks-10413

---

## Company Snapshot

Larimar Therapeutics (NASDAQ: LRMR) is a clinical-stage biotechnology company focused on rare diseases using its cell-penetrating peptide (intracellular delivery) platform. Its lead candidate, nomlabofusp (formerly CTI-1601), is being evaluated in a Phase 2 program as a potential treatment for Friedreich's ataxia (FA), a rare, progressive genetic disease [[12]](https://larimartx.com/news/)[[16]](https://www.tipranks.com/stocks/lrmr/drug-pipeline)[[19]](https://finance.yahoo.com/quote/LRMR/). As of late October 2026, the stock trades near the low end of its 52-week range ($1.92–$6.42), at roughly $2.5–2.7, with a market capitalization of ~$257M and negative trailing EPS of -$1.99 [[19]](https://finance.yahoo.com/quote/LRMR/).

## Recent Catalysts (July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-lrmr-larimar-therapeutics-inc-catalysts-narrative-risks-10413 (free to sign up)._